241 related articles for article (PubMed ID: 17277711)
1. Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies.
Christensen DD
CNS Spectr; 2007 Feb; 12(2):113-6, 119-23. PubMed ID: 17277711
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying therapies in Alzheimer's disease: how far have we come?
Hüll M; Berger M; Heneka M
Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
4. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
5. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
6. Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.
Christensen DD
Prim Care Companion J Clin Psychiatry; 2007; 9(1):32-41. PubMed ID: 17599166
[TBL] [Abstract][Full Text] [Related]
7. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
8. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
9. Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.
Höglund K; Blennow K
CNS Drugs; 2007; 21(6):449-62. PubMed ID: 17521225
[TBL] [Abstract][Full Text] [Related]
10. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
11. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
13. Can statins put the brakes on Alzheimer's disease?
Whitfield JF
Expert Opin Investig Drugs; 2006 Dec; 15(12):1479-85. PubMed ID: 17107274
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.
Blennow K; Hampel H; Zetterberg H
Neuropsychopharmacology; 2014 Jan; 39(1):189-201. PubMed ID: 23799530
[TBL] [Abstract][Full Text] [Related]
15. Non-cholinergic strategies for treating and preventing Alzheimer's disease.
Doraiswamy PM
CNS Drugs; 2002; 16(12):811-24. PubMed ID: 12421115
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and Toxicological Properties of the Potent Oral
Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
[TBL] [Abstract][Full Text] [Related]
17. Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies.
Vijayan D; Chandra R
Curr Drug Targets; 2020; 21(2):148-166. PubMed ID: 31385768
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies for Alzheimer's disease in clinical trials.
Godyń J; Jończyk J; Panek D; Malawska B
Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.
Zhang L; Song L; Terracina G; Liu Y; Pramanik B; Parker E
Biochemistry; 2001 Apr; 40(16):5049-55. PubMed ID: 11305921
[TBL] [Abstract][Full Text] [Related]
20. Identification of a BACE1 Binding Peptide Candidate for the Prevention of Amyloid Beta in Alzheimer's Disease.
Read J; Suphioglu C
Cell Physiol Biochem; 2019; 53(2):413-428. PubMed ID: 31415717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]